These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17362901)

  • 1. Enzymes and pharmacogenetics of cardiovascular drugs.
    Siest G; Jeannesson E; Visvikis-Siest S
    Clin Chim Acta; 2007 May; 381(1):26-31. PubMed ID: 17362901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the genetic causes of inter-patient variability. Clinical relevance with focus on cardiovascular drugs.
    Ginghină C; Stănescu R; Coman IM; Bărbari L; Popescu BA
    Rom J Intern Med; 2007; 45(4):313-9. PubMed ID: 18767405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of heart failure -- focus on drug disposition and action.
    Cascorbi I; Paul M; Kroemer HK
    Cardiovasc Res; 2004 Oct; 64(1):32-9. PubMed ID: 15364611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.
    Sikka R; Magauran B; Ulrich A; Shannon M
    Acad Emerg Med; 2005 Dec; 12(12):1227-35. PubMed ID: 16282513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.
    Murray M
    J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates on cytochrome P450-mediated cardiovascular drug interactions.
    Cheng JW; Frishman WH; Aronow WS
    Am J Ther; 2009; 16(2):155-63. PubMed ID: 19114873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Individualized pharmacotherapy based on cytochrome P-450 (CYP) genotyping].
    Johansen PW; Bergan S; Rootwelt H; Kvittingen EA; Rugstad HE
    Tidsskr Nor Laegeforen; 2002 Nov; 122(29):2781-3. PubMed ID: 12523145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DMET microarray technology for pharmacogenomics-based personalized medicine.
    Burmester JK; Sedova M; Shapero MH; Mansfield E
    Methods Mol Biol; 2010; 632():99-124. PubMed ID: 20217574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics of drugs affecting the cardiovascular system.
    Siest G; Ferrari L; Accaoui MJ; Batt AM; Visvikis S
    Clin Chem Lab Med; 2003 Apr; 41(4):590-9. PubMed ID: 12747607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
    Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
    Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of analgesics: toward the individualization of prescription.
    Rollason V; Samer C; Piguet V; Dayer P; Desmeules J
    Pharmacogenomics; 2008 Jul; 9(7):905-33. PubMed ID: 18597654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 pharmacogenetics and cancer.
    Rodriguez-Antona C; Ingelman-Sundberg M
    Oncogene; 2006 Mar; 25(11):1679-91. PubMed ID: 16550168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic factors in drug metabolism.
    Belle DJ; Singh H
    Am Fam Physician; 2008 Jun; 77(11):1553-60. PubMed ID: 18581835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 enzymes and the heart.
    Chaudhary KR; Batchu SN; Seubert JM
    IUBMB Life; 2009 Oct; 61(10):954-60. PubMed ID: 19787709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies.
    Saggar S; Maibach HI
    Cutan Ocul Toxicol; 2007; 26(3):171-80. PubMed ID: 17687682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacogenetics--new perspectives in the treatment of cardiovascular diseases].
    Dzida G
    Kardiol Pol; 2004 Mar; 60(3):304-8. PubMed ID: 15156230
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.